In clinical studies, BAFFR-Ig has been shown to inhibit myeloma cell groth in both in vivo (cell culture) and ex vivo (mice) models [26]; further, a fusion toxin has been developed for BLyS receptors such as BAFF-R with cytotoxic effects inhibited when pretreated with soluble BAFF-R decoy receptors [27] A SNP in the promoter of BAFF (-871C->T, rs9514827) was previously associated with increased BAFF transcription and the -871T allele was more prevalent in familial CLL patients compared to controls [28]. This evidence concerns the gene TNFRSF13C and B-cell chronic lymphocytic leukemia.